首页|纳米放疗增敏剂在胶质瘤中的研究进展

纳米放疗增敏剂在胶质瘤中的研究进展

Recent advances in nanoradiosensitizers for glioma

扫码查看
胶质瘤是中枢神经系统最常见的原发性恶性肿瘤,具有高度侵袭性,预后相对较差.在胶质瘤的综合治疗中,放疗是最常用且有效的手段之一.然而,胶质瘤对放疗的抵抗性以及放疗产生的副反应仍然是不可避免的问题.近年来,随着纳米技术在医学领域的快速发展,纳米放疗增敏剂凭借其独特的理化性质,在胶质瘤的治疗中受到广泛关注,为增强放疗疗效提供了新机遇.本文阐述了纳米放疗增敏剂在胶质瘤中的应用,总结和展望了纳米放疗增敏剂在应用中面临的挑战和发展前景.
Glioma are the most common primary malignant tumors of the central nervous system,with high invasiveness and relatively poor prognosis.In the comprehensive treatment of glioma,radiotherapy is one of the most commonly used and effective methods.However,the resistance of glioma to radiotherapy and the side effects caused by radiotherapy are still inevitable issues.In recent years,with the rapid development of nanotechnology in the medical field,nano radiotherapy sensitizers have received widespread attention in the treatment of gliomas due to their unique physicochemical properties,providing new opportunities for enhancing radiotherapy efficacy.This article elaborates on the application of nanoradiotherapy sensitizers in gliomas,summarizes and prospects the challenges and development prospects faced by nanoradiotherapy sensitizers in their application.

nanoradiosensitizersgliomaradiotherapyradiosensitization strategiesdrug delivery

刘明熙、唐祥龙、肖红、刘宏毅

展开 >

210029 南京,南京医科大学附属脑科医院神经外科

210029 南京,南京医科大学附属脑科医院研究所

纳米放疗增敏剂 胶质瘤 放射治疗 放疗增敏策略 药物递送

国家自然科学基金委员会资助项目

81902535

2024

临床神经外科杂志
南京医科大学附属脑科医院

临床神经外科杂志

CSTPCD
影响因子:1.019
ISSN:1672-7770
年,卷(期):2024.21(5)